Inhibiting DNA methylation improves antitumor immunity in ovarian cancer.
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
Cancer cells resist the immune response in a process known as immune editing or immune evasion. Therapies that target the immune system have revolutionized cancer treatment; however, immunotherapies have been ineffective for the majority of ovarian cancer cases. In this issue of the JCI, Chen, Xie, et al. hypothesized that hypomethylating agent (HMA) treatment would induce antitumor immunity to sensitize patients with ovarian cancer to anti-PD-1 immunotherapy. The authors performed a phase II clinical trial to test the combination of guadecitabine, a second-generation HMA, along with pembrolizumab, an immune checkpoint inhibitor of PD-1. The trial included a group of 35 patients with platinum-resistant ovarian cancer. While the clinical benefit from the combined HMA plus immune checkpoint blockade regimen was lower than hoped, the correlate analyses gave important information about which patients with ovarian cancer may be more likely to respond to immune therapy.
Identifiants
pubmed: 35838045
pii: 160186
doi: 10.1172/JCI160186
pmc: PMC9282922
doi:
pii:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R37 CA251270
Pays : United States
Commentaires et corrections
Type : CommentOn
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nat Cancer. 2021 Oct;2(10):1002-1017
pubmed: 34790902
Oncoimmunology. 2019 Oct 16;9(1):1659093
pubmed: 32002281
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Oncotarget. 2014 Feb 15;5(3):587-98
pubmed: 24583822
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Immunol Res. 2015 Sep;3(9):1030-41
pubmed: 26056145
Clin Cancer Res. 2019 Dec 15;25(24):7351-7362
pubmed: 31530631
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Cell. 2022 Mar 31;185(7):1208-1222.e21
pubmed: 35305314
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753546
FEBS J. 2022 Mar;289(5):1160-1179
pubmed: 33471418
Lancet Oncol. 2017 Oct;18(10):1317-1326
pubmed: 28844816
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancer Cell. 2012 Mar 20;21(3):430-46
pubmed: 22439938
Clin Cancer Res. 2005 May 15;11(10):3604-8
pubmed: 15897554
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17785-17795
pubmed: 32651270
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14007-12
pubmed: 10570189
J Clin Invest. 2022 Jul 15;132(14):
pubmed: 35671108
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990
pubmed: 29203668
Nature. 2015 Nov 12;527(7577):249-53
pubmed: 26503055
Cell. 2017 Nov 30;171(6):1284-1300.e21
pubmed: 29195073
Nat Rev Genet. 2016 Sep 15;17(10):630-41
pubmed: 27629931
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071